Passa al contenuto
Merck

Alzheimer's disease and cholesterol: the fat connection.

Neurochemical research (2006-12-28)
Laura Canevari, John B Clark
ABSTRACT

Since the discovery of the significance of the cholesterol-carrying apolipoprotein E and cholesterolaemia as major risk factors for Alzheimer's Disease (AD) there has been a mounting interest in the role of this lipid as a possible pathogenic agent. In this review we analyse the current evidence linking cholesterol metabolism and regulation in the CNS with the known mechanisms underlying the development of Alzheimer's Disease. Cholesterol is known to affect amyloid-beta generation and toxicity, although it must be considered that the results studies using the statin class of drugs to lower plasma cholesterol may be affected by other effects associated with these drugs. Finally, we report some of our results pointing at the interplay between neurons and astrocytes and NADPH oxidase activation as a new candidate mechanism linking cholesterol and AD pathology.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide 2′-fosfato ridotto, ≥93% (HPLC)
Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide 2′-fosfato ridotto, ≥97% (HPLC)
Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide fosfato
Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide 2′-fosfato ridotto, ≥95% (HPLC)
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide phosphate, reduced tetra(cyclohexylammonium) salt, ≥93%
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 5 mg (per vial)
Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide 2′-fosfato ridotto, vial of 0.30-0.36 mg
Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide 2′-fosfato ridotto, vial of 10 mg, ~95%
Sigma-Aldrich
β-Nicotinamide adenine dinucleotide phosphate sodium salt, pkg of 10 mg (per vial)
Sigma-Aldrich
ββ-Nicotinamide adenina dinucleotide 2′-fosfato ridotto, vial of 5 mg